908 DEVICES INC (MASS)
Information Technology · Handheld analytical instruments / point-of-need chemical analysis · NASDAQ
908 Devices miniaturizes mass spectrometry and optical spectroscopy into handheld devices that deliver real-time chemical analysis at the point of need for frontline workers combating the opioid crisis and detecting security threats.
What 908 DEVICES INC does
908 Devices develops and sells purpose-built handheld devices for point-of-need chemical analysis, leveraging miniaturized mass spectrometry and optical spectroscopy technologies. The company's handheld devices—including MX908, ThreatID, ProtectIR, XplorIR, and VipIR—enable rapid identification of unknown materials in critical applications including detection of fentanyl and illicit drugs, toxic carcinogens, and security threats. Using semiconductor microfabrication techniques to miniaturize mass spectrometry instruments and combining them with complementary vibrational spectroscopy capabilities acquired through RedWave Technology, 908 Devices delivers laboratory-grade analytical answers where and when they are needed in the field.
Themes: ["Point-of-need chemical analysis","Handheld mass spectrometry","Fentanyl / opioid crisis detection","Toxic carcinogen exposure detection","Global security / threat detection","Counterfeit pharmaceutical detection","Laboratory instrument miniaturization","Optical spectroscopy / vibrational spectroscopy"]
Fundamentals
- Price$8.13 as of 2026-07-09 close
- Market cap$307M as of 2026-07-10
- 1-year return+15.7% as of 2026-07-09 close
- P/E15.77 as of 2026-07-10
- Net margin-62.4% as of 2026-07-10
- Gross margin+51.5% as of 2026-07-10
- ROE-25.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-5.9% as of 2026-07-10
- Revenue CAGR (3y)+6.2% SEC XBRL
- Beta0.62 as of 2026-07-10
Key risks (from latest filing)
["Competitive pressure from large established manufacturers of laboratory-based instruments and new market entrants could limit market share and pricing power","Reliance on government and agency customers for significant revenue creates dependence on government funding and budgeting cycles","Heavy operating losses (net margin -62.4%) and declining revenue (-5.89% YoY) suggest execution challenges in scaling the business profitably"]
Competitors & peers
- Thermo Fisher Scientific
- PerkinElmer
- Shimadzu
- Waters Corporation
- Agilent Technologies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.